The PET-CT Scanner Device Market, estimated at USD 2.45 Bn in 2025, is expected to exhibit a CAGR of 6.1% and reach USD 3.71 Bn by 2032.
The industry is experiencing robust growth fueled by increasing demand for advanced imaging technologies that enable early and precise disease diagnosis. Continuous innovations in MRI, CT, PET, and ultrasound systems, along with the integration of AI and cloud-based imaging platforms, are transforming clinical workflows and improving patient outcomes. Moreover, rising healthcare expenditure, supportive regulatory initiatives, and expanding access to modern diagnostic facilities are creating strong opportunities for market expansion.
Market Dynamics:
Increasing cancer prevalence: According to WHO, cancer burden has risen to 18.1 million new cases and 9.6 million cancer deaths in 2018 worldwide. PET-CT scans enable better cancer diagnosis and treatment monitoring and thus its demand is surging significantly.
Growing demand for minimally invasive diagnostic procedures: The demand for less complex diagnostic methods is increasing among healthcare providers and patients alike. PET-CT scanner provides combined anatomic-metabolic imaging ability with one single procedure which is less time-consuming and invasive than multiple individual tests. This increasing preference for simplified procedures will augment the PET-CT scanner market growth over the forecast period.
Increasing Prevalence of Chronic Diseases Drives Demand for PET-CT Scanners
One of the primary drivers fueling growth in the Global PET-CT Scanner Device Market is the rising prevalence of chronic diseases globally. Diseases such as cancer, heart disease and neurological disorders are becoming increasingly common. PET-CT scanners play a vital role in the diagnosis and staging of these conditions. Their ability to provide both anatomic and functional information makes them highly valuable for detecting diseases at an early stage when treatment outcomes are optimal. With lifestyle changes and improved healthcare contributing to growing life expectancy worldwide, chronic illnesses requiring PET-CT scans for management are on the rise. This sustained increase in underlying disease burden ensures stable long-term demand for PET-CT scanning services and equipment.
Technological Advancements Expand Clinical Applications
Constant innovations that enhance the capabilities of PET-CT scanners represent another key driver for market expansion. New features such as improved resolution, shortened scan times and advanced analytics software allow these systems to be utilized for a widening scope of clinical uses. Beyond oncology, areas seeing expanded PET-CT adoption include cardiology, neurology and infection imaging. Simultaneous acquisition of molecular and anatomic data enables high-resolution imaging of biological processes in vivo. The introduction of innovative technologies such as time-of-flight detection and point spread function modeling has significantly boosted scanner precision and diagnostic value. This encourages greater uptake among hospitals and imaging centers seeking to offer advanced molecular imaging services. Continuous technological refinement thus maintains market momentum by expanding clinical relevance and facilitating new clinical applications for PET-CT scanners over time.
Reimbursement Uncertainties Hamper Market Growth
However, uncertainties surrounding insurance coverage and reimbursement policies pose a restraint on the PET-CT Scanner Device Market's financial prospects. While Medicare and many private payers cover PET-CT exams for approved oncology indications, coverage criteria vary considerably between different providers and territories. Restrictive guidelines, delays in approval for new uses and inadequate payment levels create disincentives for healthcare facilities to invest in cutting-edge scanners. This is a particular issue in cost-sensitive countries where public funds dominate healthcare spending. Complex reimbursement landscapes inhibit standardized access to PET-CT technologies and restrict the market to wealthy nations or those with generous coverage policies. Overcoming inconsistent reimbursement norms across global regions remains a challenge limiting stronger market expansion.
High Capital Investments Require Substantial Budgets
Another major restraint is the substantial upfront capital required for purchasing PET-CT systems. Top-of-the-line equipment can cost over US$ 3 million, significant maintenance costs are ongoing, and suitable facilities are also needed. The high barrier to entry discourages all but the largest hospitals and imaging centers from investing in these technologies. Budgetary constraints are a serious impediment especially in developing countries where public healthcare spending must be prioritized for basic services over high-capital investments. Financing arrangements may help address this issue to some extent but high costs continue restricting the PET-CT scanner installation base to major academic medical centers and well-funded private providers. Addressing the challenges of large capital outlays could help spur wider global market access.
Opportunity for Mobile Units in Rural Regions
One opportunity area is the deployment of mobile PET-CT units to expand access in underserved rural communities. Transporting scanners on specialized vehicles helps bring molecular imaging capabilities nearer to remote patient populations who would otherwise face long travel times to urban centers. This addresses a current lack of local availability that results in treatment delays. Mobile PET-CT could particularly benefit developing countries struggling with geographic inequities in healthcare resources. However, regulatory and logistical hurdles may need to be overcome regarding mobile unit operations and reimbursement in different jurisdictions.
Growing Research Applications Present Development Prospects
Building partnerships between medical device companies and research institutes represents another market opportunity. PET-CT technologies show promise for advancing basic science in fields such as drug development, gene therapy and disease modeling. Novel tracers continue expanding their research utility beyond existing clinical scenarios. Technology developers could tap this avenue by collaborating on projects that validate PET-CT’s role in accelerating scientific progress. Success in non-clinical domains may attract research funding to drive further platform enhancements. This collaborative R&D approach offers business prospects for scanner manufacturers seeking to demonstrate cutting-edge innovation beyond patient care applications.
Link - https://www.coherentmarketinsights.com/market-insight/pet-ct-scanner-device-market-2169
Key Developments:
- In June 2024, Siemens Healthineers has introduced the Biograph Trinion, a high-performance, energy-efficient PET/CT scanner designed with a wide range of clinical capabilities and low lifetime operational costs.
- In June 2024, The newly introduced augmented whole-body scanning via magnifying PET (AWSM-PET) technology has demonstrated significant improvements in image clarity and system sensitivity for clinical whole-body PET/CT imaging.
- In April 2024, CDL Nuclear Technologies launched its cutting-edge Mobile Dedicated Cardiac PET/CT Trailer, designed to revolutionize cardiac care by delivering advanced PET/CT imaging services directly to medical facilities according to their schedules.
Key Player:
General Electric Co., Siemens Healthineers, Koninklijke Philips N.V., Canon Medical Systems, Hitachi, Ltd., Mediso Ltd., PerkinElmer, Inc., Toshiba Corporation, Bruker Corporation, Neusoft Medical Systems, Yangzhou Kindsway Biotech Co. Ltd., Shimadzu Corporation, United Imaging, Positron Corporation, MIE (Medical Imaging Electronics), Basda, MinFound Medical Systems, Radimage Technologies Pvt. Ltd., Edge Medical Solutions Pvt. Ltd., and GS Medical Imaging Private Limited
Contact Us